| Drug Name |
Medroxyprogesterone |
| Drug ID |
BADD_D01365 |
| Description |
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties.[A14848] MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669]
Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.[L8657] |
| Indications and Usage |
Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens. |
| Marketing Status |
Not Available |
| ATC Code |
G03AC06; G03DA02; L02AB02 |
| DrugBank ID |
DB00603
|
| KEGG ID |
D08166
|
| MeSH ID |
D008525
|
| PubChem ID |
10631
|
| TTD Drug ID |
D0I2SD
|
| NDC Product Code |
54348-805; 0009-0067 |
| Synonyms |
Medroxyprogesterone | (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione | Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)- | 17 alpha-Hydroxy-6 alpha-Methylprogesterone | 17 alpha Hydroxy 6 alpha Methylprogesterone | Methylhydroxyprogesterone | Adgyn Medro |
